Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - November 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Eslicarbazepine (Zebinix®) has been accepted for restricted use after a resubmission for patients with highly refractory epilepsy who remain uncontrolled with existing anti-epileptic drugs as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

Oxycodone hydrochloride injection (OxyNorm®) has been accepted for restricted use for the treatment of moderate to severe pain in patients with cancer who have difficulty in tolerating parenteral morphine or diamorphine therapy.

Glucosamine sulphate (Glusartel®) has been rejected for use in patients for the relief of symptoms in mild to moderate osteoarthritis (OA) of the knee. The economic analysis was not sufficiently robust to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - November 2010' on Email Share 'SMC Update - November 2010' on Delicious Share 'SMC Update - November 2010' on Digg Share 'SMC Update - November 2010' on Facebook Share 'SMC Update - November 2010' on Google+ Share 'SMC Update - November 2010' on reddit Share 'SMC Update - November 2010' on StumbleUpon Share 'SMC Update - November 2010' on Twitter

atomic-wealth

No Comments to “SMC Update - November 2010”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,430 spam comments.

atomic-wealth
fond-illness
summer